BRPI1009112A2 - inibidores de tirosina quinase de bruton - Google Patents

inibidores de tirosina quinase de bruton

Info

Publication number: BRPI1009112A2
Authority: BR; Brazil
Prior art keywords: tyrosine kinase; kinase inhibitors; bruton tyrosine; bruton; inhibitors
Prior art date: 2009-03-02

Application number

BRPI1009112A

Other languages

English (en)

Inventor

Daniel Fishlock

Fariborz Firooznia

Joshua Paul Gergely Taygerly

Jun-Bae Hong

Keshab Sarma

Matthew C Lucas

Steven Joseph Berthel

Timothy D Owens

Yan Lou

Zachary Kevin Sweeney

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-02

Filing date

2010-02-25

Publication date

2016-03-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42097405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1009112(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-25 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2016-03-01 Publication of BRPI1009112A2 publication Critical patent/BRPI1009112A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Oncology (AREA)
Transplantation (AREA)
Epidemiology (AREA)

BRPI1009112A 2009-03-02 2010-02-25 inibidores de tirosina quinase de bruton BRPI1009112A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20902109P	2009-03-02	2009-03-02
US30006410P	2010-02-01	2010-02-01
PCT/EP2010/052394 WO2010100070A1 (en)	2009-03-02	2010-02-25	Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number	Publication Date
BRPI1009112A2 true BRPI1009112A2 (pt)	2016-03-01

Family

ID=42097405

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1009112A BRPI1009112A2 (pt)	2009-03-02	2010-02-25	inibidores de tirosina quinase de bruton

Country Status (20)

Country	Link
US (1)	US8299077B2 (pt)
EP (1)	EP2403846B1 (pt)
JP (1)	JP5512707B2 (pt)
KR (1)	KR101347978B1 (pt)
CN (2)	CN102341383B (pt)
AR (1)	AR076066A1 (pt)
AU (1)	AU2010220435B2 (pt)
BR (1)	BRPI1009112A2 (pt)
CA (1)	CA2753341C (pt)
CL (1)	CL2011002115A1 (pt)
ES (1)	ES2607644T3 (pt)
HK (1)	HK1216887A1 (pt)
IL (1)	IL214351A0 (pt)
MX (1)	MX339583B (pt)
PE (2)	PE20120081A1 (pt)
RU (1)	RU2542585C2 (pt)
SG (1)	SG173816A1 (pt)
TW (2)	TWI519529B (pt)
WO (1)	WO2010100070A1 (pt)
ZA (1)	ZA201301679B (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8258134B2 (en) *	2008-04-16	2012-09-04	Hoffmann-La Roche Inc.	Pyridazinone glucokinase activators
ES2420854T3 (es) *	2008-07-02	2013-08-27	F. Hoffmann-La Roche Ag	Nuevas fenilpirazinonas como inhibidores de quinasas
CN105362277A (zh)	2008-07-16	2016-03-02	药品循环有限公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
EP2411393B1 (en)	2009-03-23	2014-01-22	Glenmark Pharmaceuticals S.A.	Fused pyrimidine-dione derivatives as trpa1 modulators
MX342405B (es)	2010-06-03	2016-09-28	Pharmacyclics Inc	El uso de inhibidores de la tirosina quinasa de bruton (btk).
AR082590A1 (es) *	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
US8975260B2 (en)	2010-09-01	2015-03-10	Genetech, Inc	Pyridazinones, method of making, and method of use thereof
ES2561277T3 (es)	2010-09-01	2016-02-25	Gilead Connecticut, Inc.	Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas
KR101585753B1 (ko)	2011-05-17	2016-01-14	에프. 호프만-라 로슈 아게	브루톤 티로신 키나아제의 억제제
CA2840413A1 (en) *	2011-06-28	2013-01-03	Pharmacyclics, Inc.	Methods and compositions for inhibition of bone resorption
EA201490265A1 (ru)	2011-07-13	2014-12-30	Фармасайкликс, Инк.	Ингибиторы тирозинкиназы брутона
JP5823616B2 (ja) *	2011-08-17	2015-11-25	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ブルトンチロシンキナーゼインヒビター
KR20230109775A (ko) *	2011-10-19	2023-07-20	파마싸이클릭스 엘엘씨	브루톤 티로신 인산화효소(btk)의 억제제의 용도
CN104024255B (zh) *	2011-11-03	2017-01-18	霍夫曼-拉罗奇有限公司	作为btk活性的抑制剂的烷基化哌嗪化合物
UA111756C2 (uk) *	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
TWI553004B (zh) *	2011-11-03	2016-10-11	建南德克公司	８－氟基呔－１（２ｈ）－酮化合物
MX2014006674A (es) *	2011-12-09	2014-09-04	Hoffmann La Roche	Inhibidores de tirosina cinasa de bruton.
WO2013157021A1 (en)	2012-04-20	2013-10-24	Advinus Therapeutics Limited	Bicyclic compounds, compositions and medicinal applications thereof
WO2013157022A1 (en)	2012-04-20	2013-10-24	Advinus Therapeutics Limited	Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
BR112015001690A2 (pt)	2012-07-24	2017-11-07	Pharmacyclics Inc	mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
PE20150756A1 (es)	2012-08-10	2015-06-03	Boehringer Ingelheim Int	Compuestos heteroaromaticos como inhibidores de btk
KR20150054994A (ko) *	2012-09-13	2015-05-20	에프. 호프만-라 로슈 아게	브루톤 티로신 키나아제의 억제제
KR101713465B1 (ko) *	2012-11-16	2017-03-07	에프. 호프만-라 로슈 아게	브루톤 티로신 키나아제의 억제제
CN104968346B (zh) *	2012-11-30	2017-06-27	弗·哈夫曼-拉罗切有限公司	酪氨酸蛋白激酶抑制剂
KR101737724B1 (ko)	2013-03-05	2017-05-29	에프. 호프만-라 로슈 아게	브루톤 티로신 키나아제의 억제제
BR112015021806A2 (pt) *	2013-03-05	2017-07-18	Hoffmann La Roche	inibidores de tirosina cinase de bruton
US11491154B2 (en)	2013-04-08	2022-11-08	Dennis M. Brown	Therapeutic benefit of suboptimally administered chemical compounds
EA028756B1 (ru)	2013-04-25	2017-12-29	Бэйджин, Лтд.	Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
CN104177338B (zh) *	2013-05-22	2018-04-03	南京勇山生物科技有限公司	一类布鲁顿激酶抑制剂
CN104211703B (zh) *	2013-05-30	2018-04-03	南京勇山生物科技有限公司	一类作为布鲁顿激酶抑制剂的稠杂环化合物
KR101815360B1 (ko) *	2013-07-03	2018-01-04	에프. 호프만-라 로슈 아게	헤테로아릴 피리돈 및 아자-피리돈 아마이드 화합물
ES2699452T3 (es) *	2013-07-26	2019-02-11	Carna Biosciences Inc	Nuevo derivado de triazina
WO2015013579A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Compositions to improve the therapeutic benefit of bisantrene
ES2709509T3 (es)	2013-08-12	2019-04-16	Pharmacyclics Llc	Procedimientos para el tratamiento de cáncer amplificado por HER2
PL3702373T3 (pl)	2013-09-13	2022-12-05	Beigene Switzerland Gmbh	Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
US9512084B2 (en) *	2013-11-29	2016-12-06	Novartis Ag	Amino pyrimidine derivatives
JP6275846B2 (ja) *	2013-12-05	2018-02-07	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物
CN105722834B (zh) *	2013-12-13	2017-12-22	豪夫迈·罗氏有限公司	酪氨酸蛋白激酶抑制剂
US9885086B2 (en)	2014-03-20	2018-02-06	Pharmacyclics Llc	Phospholipase C gamma 2 and resistance associated mutations
CN110156892B (zh)	2014-07-03	2023-05-16	百济神州有限公司	抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN106922146B (zh) *	2014-10-02	2020-05-26	豪夫迈·罗氏有限公司	用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
CN104402828A (zh) *	2014-11-05	2015-03-11	定陶县友帮化工有限公司	一种3-氨基-4-溴-6-氯哒嗪的合成方法
TW201702218A (zh)	2014-12-12	2017-01-16	美國杰克森實驗室	關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3042903B1 (en)	2015-01-06	2019-08-14	Impetis Biosciences Ltd.	Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
RS60411B1 (sr)	2015-07-02	2020-07-31	Acerta Pharma Bv	Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida
RU2608128C1 (ru) *	2015-11-12	2017-01-13	федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России)	Способ лечения больных с х-сцепленной агаммаглобулинемией
US10570118B2 (en) *	2016-01-13	2020-02-25	Boehringer Ingelheim International Gmbh	Isoquinolones as BTK inhibitors
CN109476666B (zh) *	2016-06-22	2021-10-15	上海复尚慧创医药研究有限公司	一种作为激酶抑制剂的化合物
WO2018007885A1 (en)	2016-07-05	2018-01-11	Beigene, Ltd.	COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
KR20190035769A (ko)	2016-07-21	2019-04-03	바이오젠 엠에이 인코포레이티드	브루톤 타이로신 카이나제 저해제의 석신에이트 형태 및 조성물
MX384627B (es)	2016-08-16	2025-03-14	Beigene Ltd	Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxifenil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma
AU2017313085B2 (en)	2016-08-19	2024-06-20	Beone Medicines I Gmbh	Use of a combination comprising a Btk inhibitor for treating cancers
BR112019005337A2 (pt)	2016-09-19	2019-08-27	Mei Pharma Inc	terapia combinada
JP6890179B2 (ja)	2016-12-02	2021-06-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	二環式アミド化合物及びその使用方法
US11590167B2 (en)	2016-12-03	2023-02-28	Juno Therapeutic, Inc.	Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
EP3573989A4 (en)	2017-01-25	2020-11-18	Beigene, Ltd.	CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
AU2018290532A1 (en)	2017-06-26	2019-11-21	Beigene, Ltd.	Immunotherapy for hepatocellular carcinoma
CA3067944C (en)	2017-07-14	2023-03-14	F. Hoffmann-La Roche Ag	Bicyclic ketone compounds and methods of use thereof
CN110997677A (zh)	2017-08-12	2020-04-10	百济神州有限公司	具有改进的双重选择性的Btk抑制剂
KR102613433B1 (ko)	2017-10-11	2023-12-13	주식회사 대웅제약	신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
CA3078688A1 (en)	2017-10-31	2019-05-09	F. Hoffmann-La Roche Ag	Bicyclic sulfones and sulfoxides and methods of use thereof
WO2019108795A1 (en)	2017-11-29	2019-06-06	Beigene Switzerland Gmbh	Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
EP3728228A1 (en)	2017-12-22	2020-10-28	Ravenna Pharmaceuticals, Inc.	Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN111961035B (zh) *	2019-05-20	2022-11-01	南京科技职业学院	一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
CN113939289A (zh)	2019-06-10	2022-01-14	百济神州瑞士有限责任公司	一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
TW202112767A (zh)	2019-06-17	2021-04-01	美商佩特拉製藥公司	作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EP4545537A3 (en) *	2021-05-05	2025-07-16	F. Hoffmann-La Roche AG	Process for preparing btk inhibitors
WO2023152888A1 (ja) *	2022-02-10	2023-08-17	カルナバイオサイエンス株式会社	フルオロイソキノリン化合物およびその製造法
US11786531B1 (en)	2022-06-08	2023-10-17	Beigene Switzerland Gmbh	Methods of treating B-cell proliferative disorder
CN119080748A (zh) *	2024-08-29	2024-12-06	中南大学	一种靶向brd7抑瘤蛋白的增稳剂及其在制备治疗实体肿瘤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7312341B2 (en)	2002-09-09	2007-12-25	Cgi Pharmaceuticals, Inc.	6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
WO2005014599A1 (en)	2003-06-04	2005-02-17	Cellular Genomics, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
ATE500227T1 (de) *	2004-12-24	2011-03-15	Astrazeneca Ab	Amidderivate
PE20080839A1 (es)	2006-09-11	2008-08-23	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20081370A1 (es)	2006-09-11	2008-11-28	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CA2909988A1 (en) *	2007-10-23	2009-04-30	F. Hoffmann-La Roche Ag	Kinase inhibitors
ES2462642T3 (es)	2007-12-14	2014-05-26	F. Hoffmann-La Roche Ag	Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
US7683064B2 (en)	2008-02-05	2010-03-23	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
EP2242749B1 (en) *	2008-02-05	2013-04-10	F. Hoffmann-La Roche AG	Novel pyridinones and pyridazinones
PE20100851A1 (es) *	2008-06-24	2011-01-31	Hoffmann La Roche	PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
ES2420854T3 (es)	2008-07-02	2013-08-27	F. Hoffmann-La Roche Ag	Nuevas fenilpirazinonas como inhibidores de quinasas

2010
- 2010-02-24 US US12/711,312 patent/US8299077B2/en not_active Expired - Fee Related
- 2010-02-25 JP JP2011552393A patent/JP5512707B2/ja not_active Expired - Fee Related
- 2010-02-25 CN CN201080010268.3A patent/CN102341383B/zh not_active Expired - Fee Related
- 2010-02-25 CN CN201510400556.4A patent/CN105001206A/zh active Pending
- 2010-02-25 KR KR1020117020555A patent/KR101347978B1/ko not_active Expired - Fee Related
- 2010-02-25 RU RU2011140064/04A patent/RU2542585C2/ru not_active IP Right Cessation
- 2010-02-25 ES ES10705373.8T patent/ES2607644T3/es active Active
- 2010-02-25 EP EP10705373.8A patent/EP2403846B1/en not_active Not-in-force
- 2010-02-25 PE PE2011001551A patent/PE20120081A1/es not_active Application Discontinuation
- 2010-02-25 SG SG2011060654A patent/SG173816A1/en unknown
- 2010-02-25 MX MX2011008643A patent/MX339583B/es active IP Right Grant
- 2010-02-25 AU AU2010220435A patent/AU2010220435B2/en not_active Ceased
- 2010-02-25 BR BRPI1009112A patent/BRPI1009112A2/pt not_active IP Right Cessation
- 2010-02-25 CA CA2753341A patent/CA2753341C/en not_active Expired - Fee Related
- 2010-02-25 PE PE2015001561A patent/PE20151336A1/es not_active Application Discontinuation
- 2010-02-25 WO PCT/EP2010/052394 patent/WO2010100070A1/en not_active Ceased
- 2010-03-01 TW TW099105838A patent/TWI519529B/zh not_active IP Right Cessation
- 2010-03-01 TW TW103123368A patent/TW201439080A/zh unknown
- 2010-03-01 AR ARP100100592A patent/AR076066A1/es unknown
2011
- 2011-07-28 IL IL214351A patent/IL214351A0/en not_active IP Right Cessation
- 2011-08-30 CL CL2011002115A patent/CL2011002115A1/es unknown
2013
- 2013-03-05 ZA ZA2013/01679A patent/ZA201301679B/en unknown
2016
- 2016-04-26 HK HK16104764.8A patent/HK1216887A1/zh unknown

Also Published As

Publication number	Publication date
TWI519529B (zh)	2016-02-01
HK1216887A1 (zh)	2016-12-09
SG173816A1 (en)	2011-09-29
MX339583B (es)	2016-06-01
CA2753341C (en)	2017-02-21
JP5512707B2 (ja)	2014-06-04
TW201439080A (zh)	2014-10-16
AR076066A1 (es)	2011-05-18
US20100222325A1 (en)	2010-09-02
KR101347978B1 (ko)	2014-01-14
IL214351A0 (en)	2011-09-27
PE20120081A1 (es)	2012-02-06
KR20110111325A (ko)	2011-10-10
CN105001206A (zh)	2015-10-28
CN102341383A (zh)	2012-02-01
ES2607644T3 (es)	2017-04-03
CN102341383B (zh)	2015-09-16
HK1164859A1 (en)	2012-09-28
PE20151336A1 (es)	2015-09-18
US8299077B2 (en)	2012-10-30
RU2011140064A (ru)	2013-04-10
EP2403846B1 (en)	2016-11-02
TW201035072A (en)	2010-10-01
CA2753341A1 (en)	2010-09-10
EP2403846A1 (en)	2012-01-11
WO2010100070A1 (en)	2010-09-10
ZA201301679B (en)	2015-06-24
JP2012519200A (ja)	2012-08-23
RU2542585C2 (ru)	2015-02-20
CL2011002115A1 (es)	2012-03-30
MX2011008643A (es)	2011-09-06
AU2010220435A1 (en)	2011-08-18
AU2010220435B2 (en)	2015-12-24

Publication	Publication Date	Title
FR25C1006I1 (fr)	2025-04-04	Inhibiteurs de pyrazolyl-quinoxaline kinase
BRPI1009112A2 (pt)	2016-03-01	inibidores de tirosina quinase de bruton
IL280173A (en)	2021-03-01	Inhibitors of brutons tyrosine kinase
CY2019009I1 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
BR112014000653A2 (pt)	2017-02-14	inibidores de tirosina quinase de bruton
BR112013029620A2 (pt)	2016-09-06	inibidores de tirosina quinase de bruton
ES2590905T8 (es)	2020-12-09	Inhibidores de la tirosina quinasa de Bruton
EP2498607A4 (en)	2013-06-19	Kinase Inhibitors
EP2493313A4 (en)	2013-05-15	Kinase Inhibitors
EP2473049A4 (en)	2013-02-13	Bruton's tyrosine kinase inhibitors
CY2017012I1 (el)	2017-11-14	Αναστολεις κινασης τυροσινης bruton
EP2515657A4 (en)	2013-07-03	Tyrosine kinase inhibitor
BRPI0910668A2 (pt)	2019-09-24	inibidores de proteína quinases
EP2632898A4 (en)	2014-04-02	HETEROCYCLIC TYROSINE KINASE HEMMER
EP2558099A4 (en)	2013-07-17	Kinase inhibitors
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
EP2519517A4 (en)	2013-05-15	TYPE II RAF KINASE INHIBITORS
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI1011129A2 (pt)	2016-11-01	métodos e compostos inibidores de janus cinase
IL230561A0 (en)	2014-03-31	Inhibitors of bruton's tyrosine kinsae
BRPI0908494A2 (pt)	2015-08-11	Inibidores de pirrolopirazina quinase
BR112012000525A2 (pt)	2015-09-15	inibidores da bace
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
BRPI1013623A2 (pt)	2016-04-19	inibidores de ligação de proteína cinase

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-12-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-04-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]